Skip to main content
CLEARBRIDGE HEALTH LIMITED logo

CLEARBRIDGE HEALTH LIMITED — Investor Relations & Filings

Ticker · 1H3 ISIN · SG1EB6000000 LEI · 222100CS4CBG4MYP7R27 SGX Human health and social work activities
Filings indexed 44 across all filing types
Latest filing 2026-05-06 AGM Information
Country SG Singapore
Listing SGX 1H3

About CLEARBRIDGE HEALTH LIMITED

https://clearbridgemedical.com/

Clearbridge Health Limited is an integrated healthcare group focused on delivering precision medicine across Asia. Its core businesses encompass the provision of laboratory testing services, ownership and operation of medical clinics and centers, and strategic equity investments. The group specializes in innovative solutions for early detection of cancer, critical diseases, genetic risks, and chronic conditions. It provides personalized care by leveraging individual genomic and metabolomic profiles for targeted preventive or intervention treatments. A key offering is immune cell banking through Cell Entrust, enabling individuals to store their own immune cells for future personalized medicine applications. The company utilizes global expertise and advanced technologies through international partnerships to bring cutting-edge products and services to the market.

Recent filings

Filing Released Lang Actions
General Announcement::Minutes of the Annual General Meeting Held on 23 April 2026
AGM Information Classification · 95% confidence The document is the formal Minutes of the Annual General Meeting (AGM) of Clearbridge Health Limited, detailing the date, time, location, chairperson, resolutions tabled, poll voting procedures, and results. It is not the full annual report or financial statements themselves, nor an announcement of a future report. It records the proceedings and materials of the AGM, fitting the AGM Information category.
2026-05-06 English
Asset Acquisitions and Disposals::DISPOSAL OF SUBSIDIARIES
M&A Activity Classification · 85% confidence The document is a formal announcement by Clearbridge Health Limited detailing the sale of a wholly-owned subsidiary, including SPA terms, consideration, pro forma financial effects under the Catalist Rules, and regulatory references to Rule 1006. This is an announcement of a corporate transaction (disposal of subsidiaries), which falls under M&A Activity. It is not a full financial report, call transcript, or remuneration report. Therefore, the appropriate classification is M&A Activity (TAR).
2026-05-04 English
General Announcement::RESPONSE TO QUESTIONS RECEIVED FROM SIAS
Regulatory Filings
2026-04-22 English
Annual Reports and Related Documents::
Regulatory Filings
2026-04-07 English
Annual General Meeting::Voluntary
Regulatory Filings
2026-04-07 English
REPL::Annual General Meeting::Voluntary
Regulatory Filings
2026-04-07 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.